This information was originally presented as part of the NCCN 2015 Breast Cancer Congress Webinar Series.

This information was originally presented at the NCCN 20th Annual Conference: Advancing the Standard of Cancer Care™ held in Hollywood, Florida.

These NCCN Guideline Insights highlight the important updates to the systemic therapy recommendations in the 2016 NCCN Guidelines for Breast Cancer.

Join Kathleen Horst, MD and Melinda Telli, MD as they present their multidisciplinary expertise on a range of cases pertaining to locally advanced disease breast cancer.

Purpose: Persistent pain after breast cancer treatment (PPBCT) affects 25% to 60% of breast cancer survivors and is recognized as a clinical problem, with 10% to 15% reporting moderate to severe pain several years after treatment.

Evidence from randomized clinical trials supports the use of tamoxifen, raloxifene, exemestane, and anastrozole for the reduction of risk of invasive breast cancer, predominately estrogen receptor-positive tumors.

Join Kathleen Horst, MD and Melinda Telli, MD as they present their multidisciplinary expertise on a range of cases pertaining to locally advanced disease breast cancer.

This information was originally presented at the NCCN 20th Annual Conference: Advancing the Standard of Cancer Care™ held in Hollywood, Florida.

This information was originally presented at the NCCN 20th Annual Conference: Advancing the Standard of Cancer Care™ held in Hollywood, Florida.

This information was originally presented at the NCCN 20th Annual Conference: Advancing the Standard of Cancer Care™ held in Hollywood, Florida.